Tango Therapeutics Financials - Benzinga

Tango Therapeutics Inc

TNGXNASDAQ

Trade with Public

Trade with Public

$25.28

-0.19-0.75%

At close: Aug 27, 5:00 PM EST

$25.28

N/A

After Hours: 4:00 PM EST

Overview News Earnings Forecast Events Price TargetsFinancialsSentiment Ownership Compare Options Stock Report

Tango Therapeutics Financials

Tango Therapeutics (TNGX) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Tango Therapeutics Q2 EPS $(0.37) Misses $(0.32) Estimate

Tango Therapeutics (NASDAQ:TNGX) reported quarterly losses of $(0.37) per share which missed the analyst consensus estimate of $(0.32) by 15.62 percent. This is a 5.71 percent decrease over losses of $(0.35) per share

Benzinga Newsdesk

Tango Therapeutics Q4 Earnings Summary & Key Takeaways

Benzinga Insights

PRO
Tango Therapeutics Q4 EPS $(0.29) Beats $(0.33) Estimate

Tango Therapeutics (NASDAQ:TNGX) reported quarterly losses of $(0.29) per share which beat the analyst consensus estimate of $(0.33) by 11.04 percent. This is a 9.38 percent increase over losses of $(0.32) per share from

Benzinga Newsdesk

Earnings Scheduled For March 5, 2026

Benzinga Insights

Examining the Future: Tango Therapeutics's Earnings Outlook

Benzinga Insights

PRO
Tango Therapeutics' September 30 $152.8M In Cash, Cash Equivalents And Marketable Securities, in addition to $212M In October Financing Is Expected To Extend Cash Runway Into 2028

Benzinga Newsdesk